CACrown ArchivesThe cinema collection
EN/FR
Search
Menu
Research dossier · Science & Nature

Surufatinib

chemical compound

Specimen drawers, botanical folios and brass scientific instruments under study light
Science and natureInterpretive dossier study · Crown Archives visual atlas
Record originEnglish Wikipedia
Text licenseCC BY-SA 4.0
Source revisionSep 9, 2026
Entity authorityQ126122215 ↗
Source-derived summary

Surufatinib (trade name Sulanda) is pharmaceutical drug for the treatment of cancer. In China, it is approved for late-stage, well-differentiated, extrapancreatic neuroendocrine tumors.

It is also under investigation for the treatment of other types of solid tumors.

Surufatinib targets fibroblast growth factor receptor 1 (FGFR1).

Editorial summary

This brief starts where responsible research should: with the source description of “Surufatinib” as chemical compound. Everything that follows is an evidence route, not borrowed authority.

Editorial reviewA practical orientation to terminology and classification, particularly when read beside dated observations, specimens or technical literature. The current 45-word lead offers orientation but no explicit four-digit date, so chronology should not be assumed. The selected authority fields contribute no independent date. The account is most persuasive where Surufatinib, chemical and compound can be independently traced.
Editorial analysis

Why this record matters

The subject matters to the science & nature register because the source frames it as chemical compound. Its deeper value depends on whether names, dates, institutions and citations support that framing.

Evidence profile

Stable identifiers, scientific names and standards terminology offer the best bridge between this overview and specialist evidence. The source revision retrieved here is dated Sep 9, 2026. The linked authority identifier is Q126122215. None of the 0 selected statements returned an explicit reference.

Critical limits

Scientific names, classifications and consensus can change while older terminology persists in catalogues and historical literature. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.

How to read it

Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.

Best used for
  • Current terminology
  • Classification context
  • Finding cited technical literature
Verify next

Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.

Three-step research path

  1. Establish the record: confirm the title “Surufatinib”, its source revision and the description used here.
  2. Expand the search: follow Surufatinib primary sources, Surufatinib archive and Surufatinib research across catalogues and specialist indexes.
  3. Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.

Questions for further research

  1. Which source most directly establishes the central claim about “Surufatinib”?
  2. Has classification or technical consensus changed since the cited source?
  3. Is the terminology current, historical or disputed?
Subject index

Search terms from this dossier

Source & attribution

This entry incorporates text from “Surufatinib” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.